Cencora, Inc. (COR)
AI Disruption May Benefit Cencora More Than Hims & Hers
Cencora (COR) stands to benefit from AI-driven increases in prescription volumes as regulatory pilots expand automated prescribing. COR's operational leverage and AI-enabled efficiency improvements have driven adjusted operating income up 17% YoY, outpacing 4.9% sales growth. Trading at a forward GAAP P/E of 17.7x—about 25% below sector median—COR merits a 12.5% re-rating, targeting $365–$366 per share.
Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow
Cencora gets its prior buy rating reaffirmed again. Despite some market underperformance, specific business and macro fundamentals remain supportive. An investment-grade rating, positive operating cash flow, dividend safety, and an improved operating margin underscore the thesis.
Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference
Cencora NYSE: COR executives highlighted the company's specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens.
Here's Why Cencora (COR) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Here's Why Cencora (COR) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Cencora (COR) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
Why Cencora (COR) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
